Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 10, 2008, Pages 1249-1258

  Elnachef, N ^b   Scheiman, J M ^b   Fendrick, A M ^b   Howden, C W ^c   Chey, W D ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

ARTHRALGIA; ARTHRITIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG SAFETY; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HUMAN; MEDICAL PRACTICE; PERCEPTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; STOMACH PROTECTION; STOMACH ULCER; ULCER;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; DRUG PRESCRIPTIONS; HEALTH CARE SURVEYS; HUMANS; INTERNET; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; STATISTICS AS TOPIC; UNITED STATES; YOUNG ADULT;

EID: 54049127708     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03836.x     Document Type: Article

References (45)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 1999 26 (Suppl. 26 18 24.
2. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002 136: 157 60.
3. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke, 2002 updated. Consensus panel guide to comprehensive risk reductionh for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 106: 388 91.
4. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006 131: 1674 82.
5. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 2006 15: 158 64.
6. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's esophagus: a prospective study. Lancet Oncol 2005 6: 945 52.
7. Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001 110: 12S 3S.
8. Lanas A, Panes J, Pique JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003 9: 2253 66.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory durgs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 123: 241 9.
10. Lane ME, Kim MJ. Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. J Pharm Pharmacol 2006 58: 1295 304.
11. Wilcox CM, Allison J, Benzuly K, et al. Consensus Development Conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006 4: 1082 9.
12. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999 340: 1888 99.
13. Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004 20: 1539 48.
14. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006 38: 415 28.
15. Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007 133: 57 64.
16. Goldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004 20: 527 38.
17. Wong D, Wang M, Cheng Y, FitzGerald G. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005 5: 204 10.
18. Solomon SD, Wittes J, Finn PV, et al. Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008 117: 2104 13.
19. McGettigan P, Henry D. Cardiovascular risk and inhibition of cycloxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 296: 1633 44.
20. Kearny PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammtory drugs increase the risk of atherothrombosis? Meta-analys of randomized trials. BMJ 2006 332: 1302 8.
21. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008 103: 323 32.
22. Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Aliment Pharmacol Ther 2006 23: 655 68.
23. Campbell C, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardivoascular disease. A systematic review. JAMA 2007 297: 2018 24.
24. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 359: 14 22.
25. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with traditional NSAID or coxib use. Gastroenterol 2003 124: 288 92.
26. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284: 1247 55.
27. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 345: 1809 17.
28. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003 361: 573 4.
29. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002 162: 2191 202.
30. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995 311: 259 60.
31. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000 343: 834 9.
32. Derry S, Loke YK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346: 2033 88.
33. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001 85: 265 71.
34. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001 119 (Suppl 39S 63S.
35. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther 2006 24: 897 908.
36. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346: 2033 8.
37. Targownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol Ther 2008 28: 88 96.
38. Sorensen HT, Mellmkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000 95: 2218 24.
39. De Abajo FJ, Rodriquez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001 1: 1. Epub 2001 Feb 13.
40. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348: 1413 6.
41. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Int Med 2000 160: 2093 9.
42. Chan F. Management of high-risk patients on non-steroidal anti-inflammatory drugs or asprin. Drugs 2006 66 (Suppl. 1 23 8.
43. Catella-Lawson F, Reilly M, Kapoor S, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 345: 1809 17.
44. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005 142: 157 64.
45. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 330: 1366.